Related references
Note: Only part of the references are listed.Activation of Src-family tyrosine kinases in hyperproliferative epidermal disorders
Elias E. Ayli et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2008)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative'' breast cancer cell lines growing in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Epidermal hyperplasia and papillomatosis in mice with a keratinocyte-restricted deletion of csk
Kazuhisa Honda et al.
CARCINOGENESIS (2007)
C-terminal Src kinase controls development and maintenance of mouse squamous epithelia
Reiko Yagi et al.
EMBO JOURNAL (2007)
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection
Fei Huang et al.
CANCER RESEARCH (2007)
A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo
Houda Jallal et al.
CANCER RESEARCH (2007)
Srcasm corrects Fyn-induced epidermal hyperplasia by kinase down-regulation
Weijie Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib
Alan Serrels et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Skin epidermis lacking the c-myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene
Thordur Skarsson et al.
GENES & DEVELOPMENT (2006)
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells
Stephen Hiscox et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Clinical development of Src tyrosine kinase inhibitors in lung cancer
David Lee et al.
CLINICAL LUNG CANCER (2006)
Treatment for advanced tumors: Src reclaims center stage
JM Summy et al.
CLINICAL CANCER RESEARCH (2006)
Activated Src abrogates the Myc requirement for the G0/G1 transition but not for the G1/S transition
T Prathapam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells
S Nam et al.
CANCER RESEARCH (2005)
SKI-606, a Src/AbI inhibitor with in vivo activity in colon tumor xenograft models
JM Golas et al.
CANCER RESEARCH (2005)
Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis
KS Chan et al.
CANCER RESEARCH (2004)
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src
PA Plé et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression
GW McLean et al.
GENES & DEVELOPMENT (2004)
Stem-cell hierarchy in skin cancer
J Perez-Losada et al.
NATURE REVIEWS CANCER (2003)
Src family kinases in tumor progression and metastasis
JM Summy et al.
CANCER AND METASTASIS REVIEWS (2003)
A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages
S Müller-Röver et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis
T Bowman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Deregulated expression of c-Myc depletes epidermal stem cells
RL Waikel et al.
NATURE GENETICS (2001)
Regulation of c-myc expression by PDGF through Rho GTPases
M Chiariello et al.
NATURE CELL BIOLOGY (2001)
c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny
I Arnold et al.
CURRENT BIOLOGY (2001)
Share Paper
